Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML

Leukemia Research

Volumn 22, Issue 4, 1998, Pages 373-378

  Elgie, Alena W ^a   Sargent, Jean M ^a   Alton, Peter ^a   Peters, Godefridus J ^b   Noordhuis, Paul ^b   Williamson, Christine J ^a   Taylor, Colin G ^a  

^a Pembury Hospital   (United Kingdom)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

AML; Ara C; Ara CTP; Bryostatin; Drug resistance; Resistance modulation

Indexed keywords

BRYOSTATIN; CYTARABINE; CYTARABINE TRIPHOSPHATE;

ARTICLE; ASSAY; BIOACCUMULATION; BLAST CELL; CYTOTOXICITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; PRIORITY JOURNAL;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; CELL DEATH; CYTARABINE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LACTONES; LEUKEMIA, MYELOID; LEUKOCYTES, MONONUCLEAR; MACROLIDES; TETRAZOLIUM SALTS; THIAZOLES;

EID: 0032053180     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00011-3     Document Type: Article

References (29)

1. [1] Young RSK, Fischer GA. The action of arabinofuranosylcytosine on synchonously growing populations of mammalian cells. Biochem Biophys Res Commun 1968;32:23-9.
2. [2] Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, Pettit GR, Grant S. Effects of bryostatin 1 and other pharmacological activators of protein kinase C and 1-[β-D-arabinofuranosyl] cytosine-induced apoptosis in HL-60 human promyelocytic leukaemia cells. Biochem Pharmacol 1994;47:839-52.
3. [3] Hiddemann W, Jahns Streubel G, Schleyer E, Unterhalt M, Wörmann B. Proceedings 2nd International Symposium. Leukemia 1995;9:528.
4. [4] Peters GF, Jansen G. Resistance to antimetabolites. In: Schilsky RL, Milano GA, Ratain MJ, editors. Principles of Antineoplastic Drug Development and Pharmacology. New York: Marcel Dekker, 1996:543-585.
5. [5] Sonneveld P. Multidrug resistance in acute myeloid leukaemia. Bailliere's Clin Haematol 1996;9:185-203.
6. [6] Stegmann APA, Honders WH, Willemze T, et al. Transfection of wild type deoxycytidine kinase (dck)cDNA into an Ara-C and DAC resistant rat leukaemia cell line of clonal origin fully restores drug sensitivity. Blood 1995;85:1188-94.
7. [7] Chiba P, Tihan T, Eher R, Köller U, Wallner C, Göbl R, Linkesch W. Effect of cell growth and cell differentiation on 1-β-D-arabinofuranosylcytosine metabolism in myeloid cells. Br J Haematol 1989;71:451-5.
8. [8] Gunji H, Kharbanda S, Kufe D. Induction of Internucleosomal DNA fragmentation in human myeloid leukaemia cells by 1-β-D-arabinofuranosylcytosine. Cancer Res 1991;51:741-3.
9. [9] Blumberg P, Pettit GR. The bryostatins: a family of protein kinase C activators with therapeutic potential. In: Krogsgaard-Larsen P, Brøgger Christensen S, Kofod H, editors. New Leads and Targets in Drug Research, vol. 33. Copenhagen: Munksgaard, 1992:273-285.
10. [10] Huang KP. The mechanism of protein kinase C activation. Trends Neurosci 1989;12:425-32.
11. [11] Blumberg PM. Complexities of the protein kinase C pathway. Mol Carcinog 1991:4:339-44.
12. [12] Workman P. The cell membrane and cell signals: new targets for novel anticancer drugs. Ann Oncol 1990;1:100-11.
13. [13] Gescher A. Towards selective pharmacological modulation of protein kinase C - opportunities for the development of novel antineoplastic agents. Br J Cancer 1992;66:10-9.
14. [14] Basu A, Lazo JS. Protein kinase C. In: Kerr DJ, editor. New Molecular Targets for Cancer Chemotherapy. Boca Raton: CRC Press, 1994:121-141.
15. [15] Powis G. Pharmacological intervention with signal transduction. In: Veronesi U, editor. New Approaches in Cancer Pharmacology, Drug Design and Development, vol. II. Berlin: Springer-Verlag, 1994: 39-54.
16. [16] Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M, Pettit GR. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 1993:68:418-24.
17. [17] Grant S, Boise L, Westin E, Howe C, Pettit GR, Turner A, McCrady C. In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-β-D-arabinofuranosylcytosine in human leukemia cells. Biochem Pharmacol 1991;42:853-67.
18. [18] Grant S, Jarvis WD, Turner AJ, Wallace HJ, Pettit GR. Effects of bryostatin 1 and rGM-CSF on the metabolism of 1-β-D-arabinofuranosylcytosine. Br J Haematol 1992;82:522-8.
19. [19] O'Byrne KJ, Thompson C, Macaulay V, Koukourakis M, Wilner SM, Ganesan TS, Talbot DC, Harris AL. A phase II study of bryostatin in melanoma. Br J Cancer 1996;73(Suppl. XXVI):82.
20. [20] Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stern P, Young R, Brenchley P, Chang J, Pettit GR. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 1995;72:461-8.
21. [21] Philip AP, Rea D, Thavasu P, Carmichael J, Stuart NSA, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F, Harris AL. Phase I study of bryostatin 1: assessment of interleukin 6 and tumour necrosis factor α induction in vivo. J Natl Cancer Inst 1993;85:1812-8.
22. [22] Scheid C, Prendiville J, Jayson G, Crowther D, Fox B, Pettit GR, Stern PL. Immunomodulation in patients receiving intravenous bryostatin 1 in a phase I clinical study: comparison with effects of bryostatin I on lymphocyte function in vitro. Cancer Immunol Immunother 1994;39:223-30.
23. [23] Pieters R, Huismans DR, Leyva A, Veerman AJP. Comparison of the rapid automated MTT assay with a dye exlusion assay for chemosensitivity testing in childhood leukaemia. Br J Cancer 1989;59:217-20.
24. [24] Sargent JM, Taylor CG. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia. Br J Cancer 1989;60:206-10.
25. [25] Noordhuis P, Kazemier KM, Kaspers GL, Peters GF. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines. Leuk Res 1996;2:127-34.
26. [26] Elgie AW, Sargent JM, Taylor CG, Williamson C. An in vitro study of blast cell metabolism in acute myeloid leukaemia using the MTT assay. Leuk Res 1996;20:407-13.
27. [27] Van der Hem KG, Drager AM, Odding JH, Langenhuijsen MMAC, Huijgens PC. Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells. Leuk Res 1995;19:7-13.
28. [28] Ross DD. Cellular and pharmacologic aspects of drug resistance in acute myeloid leukemia. Curr Opin Oncol 1991;3:21-9.
29. [29] Kufe D, Spriggs D, Egan EM, Munroe D. Relationship among ara-CTP pools, formation of (ara-C) DNA, and cytotoxicity of leukemic cells. Blood 1984;64:54-8.